These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 24642511)

  • 1. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
    Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
    J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G; Renard D; Thouvenot E; Servillo G; Castelnovo G
    J Neurol Sci; 2014 Nov; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
    Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
    Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications.
    Greenlee JE
    Int MS J; 2006 Nov; 13(3):100-7. PubMed ID: 17101078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab.
    Mc Govern EM; Hennessy MJ
    J Neurol; 2013 Feb; 260(2):665-7. PubMed ID: 23212753
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
    Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
    Wattjes MP; Barkhof F
    Curr Opin Neurol; 2014 Jun; 27(3):260-70. PubMed ID: 24739400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.
    Phan-Ba R; Lommers E; Tshibanda L; Calay P; Dubois B; Moonen G; Clifford D; Belachew S
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):224-6. PubMed ID: 22013244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D; Giovannoni G
    Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A giant MS plaque mimicking PML during natalizumab treatment.
    Twyman C; Berger JR
    J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal supportive treatment in natalizumab-related PML in a MS patient.
    Lalive PH; Bridel C; Ferfoglia RI; Kaiser L; Du Pasquier R; Barkhof F; Haller S
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):354-5. PubMed ID: 24957322
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
    Décard BF; Haghikia A; Tönnes C; Thöne J; Lukas C; Chan A; Gold R
    Mult Scler; 2013 Feb; 19(2):249-51. PubMed ID: 22596228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ; Hogg JP
    Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.